Gavilimomab
Gavilimomab
Gavilimomab (pronunciation: gav-ill-ee-moh-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases and cancers.
Etymology
The name "Gavilimomab" follows the World Health Organization's guidelines for the International Nonproprietary Names (INN) of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the prefix "Gavili-" does not have a specific meaning and is used to create a unique name.
Usage
Gavilimomab is used in the treatment of various autoimmune diseases and cancers. It works by binding to specific proteins on the surface of cells, blocking the signals that cause the disease. This can help to reduce symptoms and slow the progression of the disease.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Autoimmune disease: A condition in which your immune system mistakenly attacks your body.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
See Also
External links
- Medical encyclopedia article on Gavilimomab
- Wikipedia's article - Gavilimomab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski